images

Roche’s neoadjuvant breast cancer combo therapy shows strong Phase 3 results

pharmafile | March 2, 2017 | News story | Research and Development Herceptin, Perjeta, Roche 

Roche’s combination treatment of Perjeta (pertuzumab), Herceptin (trasdtuzumab) and chemotherapy met its primary endpoint in a recent Phase 3 study. The therapy improved invasive disease-free survival (iDFS) in those with HER2-positive early breast cancer (eBC) when administered post-surgery, compared to Herceptin and chemotherapy alone.

Sandra Horning, Chief Medical Officer and Head of Global Product Development at Roche, commented on the findings, saying: “These results from the positive APHINITY study represent an important addition to the body of data for Perjeta in the treatment of people with HER2-positive early breast cancer. We look forward to discussing these adjuvant results with global regulatory authorities.”

The combination therapy is already licensed as a pre-surgery solution for the disease in 75 countries, and the post-therapy treatment is currently under the FDA’s accelerated approval; Roche hopes this promising new data will aid the treatment’s path to full approval.

Advertisement

Gunter von Minckwitz, Study Coordinator from the Breast International Group and academic study partners, added: “APHINITY provides yet another example of the importance of industry-academic collaborations and their value in advancing cancer care for people affected by this challenging disease.”

The aggressive HER2-positive breast cancer is known for poor prognoses and affects around 20% of breast cancer sufferers.

Matt Fellows

Related Content

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

blood_test

Roche candidate shows early promise for treating haemophilia A

Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …

Roche advances treatment for Parkinson’s disease

Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …

The Gateway to Local Adoption Series

Latest content